MedWatch

Novo Nordisk closer to launch of prize asset in Europe following new approval

Changes in the pricing strategy for Novo Nordisk's new drug hope Ozempic have caused larger regulatory problems in the EU than expected, and have impacted the launch in European countries. But the pharmaceutical company has just received an important approval, which will enable a launch in the second half of the year.

Foto: /Ritzau Scanpix/Linda Kastrup

Earlier this year, Novo Nordisk launched its long-acting GLP-1 analog Ozempic on the US market, but the launch in Europe has been much slower.

This is partly due to the fact that Novo Nordisk has changed its pricing strategy for the drug during the process, therefore the company has had to apply for approval for a new system of injection pens and this has caused certain problems in the EU.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier